Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
|Videos|July 18, 2017
How Can Pharmacy Graduates Stand Out in the Job Market?
In this clip, Melissa Hogan, PharmD, Dean of Roosevelt University College of Pharmacy, shares some advice for pharmacy students and pharmacy school graduates on how to stand out to employers in the job market.
Advertisement
In this clip, Melissa Hogan, PharmD, Dean of Roosevelt University College of Pharmacy, shares some advice for pharmacy students and pharmacy school graduates on how to stand out to employers in the job market.
Advertisement
Related to this article
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
3
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
4
Alcohol and GLP-1 Therapy: Key Counseling Points for Pharmacists
5